Locally advanced breast cancer

Ricardo Costa*, Nora M Hansen, William J Gradishar

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Locally advanced breast cancer (LABC) encompasses a wide range of breast tumors with poor prognosis, and multidisciplinary approach remains the cornerstone for the treatment of this difficult problem. Neoadjuvant chemotherapy continues to play a key role in the initial management of LABC as it allows for tumor burden reduction and increased rates of breast conserving surgery. Dual HER2-targeted therapy combined with neoadjuvant chemotherapy has further improved the rates of pathological complete response with favorable toxicity profile and should be considered an integral part of treatment along with surgery and radiation therapy. Nonetheless, despite advances in the understanding of genomic nuances of breast cancer, targeted therapies remain an unmet need for the treatment of LABC aside from HER2-positive tumors.

Original languageEnglish (US)
Title of host publicationThe Breast
Subtitle of host publicationComprehensive Management of Benign and Malignant Diseases
PublisherElsevier Inc
Pages819-831.e6
ISBN (Print)9780323359559
DOIs
StatePublished - Jan 1 2018

Keywords

  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Pathologic complete response
  • Pertuzumab
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Locally advanced breast cancer'. Together they form a unique fingerprint.

Cite this